Neoplasma · 2012 · 10 citations · 34 references
Life SciencesCell BiologyPharmacologyApoptosisCancer PharmacologyCell SignalingApoptosis In CancerApoptosis ModulationApoptosis PharmacologyApoptosis RegulationApoptotic SignalingAnti-proliferative SignalingApoptosis Signaling RegulationApoptotic Signaling PathwaysCellular ProliferationMcl-1 FunctionNf-κb SignalingStress-activated Signaling PathwaysStress-induced Apoptosis
The flavonol aglycone isorhamnetin shows anti-proliferative activity in a variety of cancer cells. Previous work, from our laboratory showed that isorhamnetin inhibits the proliferation of human esophageal squamous carcinoma Eca-109 cells in vitro, but only after 72 h of exposure. This led us to propose that isorhamnetin exposure induces a cellular stress response that inhibits the antiproliferative and apoptotic effects of the compound during early exposure. To test this hypothesis, the present study examined the effects of isorhamnetin on Eca-109 cells during the first 72 h of exposure. Cell growth was assessed using the trypan blue exclusion assay, and expression of IκBα, NF-κB/p65, NF-κB/p50, phospho-Akt, Bcl-2, COX-2, Mcl-1, Bax, p53 and Id-1 were analyzed by Western blot. During the first 72 h of exposure, NF-κB/p65 and NF-κB/p50 accumulated in nuclei and expression of COX-2, Bcl-2 and Mcl-1 increased. In contrast, expression of IκBα and Bax fell initially but later increased. Expression of phospho-Akt and p53 showed no detectable change during the first 48 h. Pretreatment with the NF-κB inhibitor MG132 before exposure to isorhamnetin blocked the nuclear accumulation of p50 and p65, thereby inhibiting cell proliferation. These results show that during early exposure of Eca-109 cells to isorhamnetin, the NF-κB signaling pathway is activated and COX-2 expression increases, and this increase in expression partially inhibits isorhamnetin-induced apoptosis. Beyond 72 h of exposure, however, the apoptotic effect of isorhamnetin dominates, leading to inhibition of the NF-κB pathway and of cellular proliferation. These results will need to be taken into account when exploring the use of isorhamnetin against cancer in vivo.
34
Cyclooxygenase in biology and disease
Raymond N. DuBois, Steven B. Abramson, Leslie J. Crofford et al. · The FASEB Journal · 1998 · 2.5K citations
Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells
Masahiko Tsujii, Sunao Kawano, Shingo Tsuji et al. · Cell · 1998 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
Naduviladath Vishvanath Chandrasekharan, Hu Dai, Katarina Roos et al. · Proceedings of the National Academy of Sciences · 2002 · 2K citations · Full text
Medicine, Biochemistry, Pharmacology +13
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Hajime Sano, Yutaka Kawahito, Ronald L. Wilder et al. · PubMed · 1995 · 1.1K citations
Medicine, Oncology, Pharmacology +10
Induction of NF-κB by the Akt/PKB kinase
Virginia Smith Shapiro, David Stokoe, Arthur Weiss · Current Biology · 1999 · 854 citations · Full text